s41467-019-10367-x.pdf (4.62 MB)
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
journal contribution
posted on 2020-01-09, 11:42 authored by Greg G Jones, Isabel Boned del Río, Sibel Sari, Aysen Sekerim, Lucy C Young, Nicole Hartig, Itziar Areso Zubiaur, Mona A El-Bahrawy, Rob E Hynds, Winnie Lei, Miriam Molina Arcas, Julian Downward, Pablo Rodriguez-VicianaTargeted inhibition of the ERK-MAPK pathway, upregulated in a majority of human cancers, has been hindered in the clinic by drug resistance and toxicity. The MRAS-SHOC2-PP1 (SHOC2 phosphatase) complex plays a key role in RAF-ERK pathway activation by dephosphorylating a critical inhibitory site on RAF kinases. Here we show that genetic inhibition of SHOC2 suppresses tumorigenic growth in a subset of KRAS-mutant NSCLC cell lines and prominently inhibits tumour development in autochthonous murine KRAS-driven lung cancer models. On the other hand, systemic SHOC2 ablation in adult mice is relatively well tolerated. Furthermore, we show that SHOC2 deletion selectively sensitizes KRAS- and EGFR-mutant NSCLC cells to MEK inhibitors. Mechanistically, SHOC2 deletion prevents MEKi-induced RAF dimerization, leading to more potent and durable ERK pathway suppression that promotes BIM-dependent apoptosis. These results present a rationale for the generation of SHOC2 phosphatase targeted therapies, both as a monotherapy and to widen the therapeutic index of MEK inhibitors.
History
Publisher DOI
Usage metrics
Categories
Keywords
AnimalsApoptosisCarcinoma, Non-Small-Cell LungCell Line, TumorDrug Resistance, NeoplasmFemaleHEK293 CellsHumansIntracellular Signaling Peptides and ProteinsLung NeoplasmsMAP Kinase Signaling SystemMaleMice, KnockoutMice, NudeMutationNeoplasm TransplantationProtein Kinase InhibitorsProtein Multimerizationraf Kinasesras ProteinsDownward FC001070
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC